Prostate Neuroendocrine Neoplasm
NCI Definition: A neoplasm with neuroendocrine differentiation that arises from the prostate gland. This category includes carcinoid tumors and small cell carcinomas. 
Prostate neuroendocrine neoplasms most frequently harbor alterations in TP53, RB1, TMPRSS2, ERG, and PTEN .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TMPRSS2-ERG Fusion, and RB1 Loss are the most common alterations in prostate neuroendocrine neoplasm .
There are 2 clinical trials for prostate neuroendocrine neoplasm, of which 1 is open and 1 is completed or closed. Of the trials that contain prostate neuroendocrine neoplasm as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open).
Avelumab, carboplatin, and etoposide are the most common interventions in prostate neuroendocrine neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.